Location History:
- Amarillo, TX (US) (2008)
- Miami, FL (US) (2003 - 2012)
Company Filing History:
Years Active: 2003-2012
Title: Jon A Weidanz: Innovator in Polyspecific Binding Molecules
Introduction
Jon A Weidanz is a notable inventor based in Miami, FL, who has made significant contributions to the field of biotechnology. He holds a total of four patents, showcasing his innovative approach to developing advanced binding molecules. His work primarily focuses on T-cell receptor technology, which has important implications for therapeutic applications.
Latest Patents
Weidanz's latest patents include groundbreaking inventions such as "Polyspecific binding molecules and uses thereof." This invention relates to single-chain polyspecific binding molecules that incorporate at least one single-chain T-cell receptor (sc-TCR) linked to a single-chain antibody (sc-Ab) through a peptide linker sequence. The patent also outlines methods and compositions for testing and utilizing these molecules. Another significant patent is "P53 binding T cell receptor molecules," which provides T-cell receptor (TCR) molecules that bind peptides derived from the human p53 protein. These TCR molecules can be heterodimeric or single-chain and are designed to specifically bind a sequence of the p53 protein displayed in the context of an HLA molecule. This invention has a wide range of applications, including therapeutic uses and detection of cells expressing p53 protein.
Career Highlights
Throughout his career, Jon A Weidanz has worked with various organizations, including Altor Bioscience Corporation. His expertise in the field has allowed him to contribute to significant advancements in biotechnology and immunology.
Collaborations
Weidanz has collaborated with notable colleagues such as Hing C Wong and Kimberlyn F Card, further enhancing the impact of his work in the scientific community.
Conclusion
Jon A Weidanz is a distinguished inventor whose work in polyspecific binding molecules has the potential to revolutionize therapeutic approaches in medicine. His innovative patents and collaborations reflect his commitment to advancing biotechnology.